Twist Bioscience Appoints Chief Ethics and Compliance Officer

SAN FRANCISCO, May 1, 2017 /PRNewswire/ -- Twist Bioscience, a company accelerating science and innovation through rapid, high-quality DNA synthesis, today announced the appointment of Mark Daniels to the newly-created position of chief ethics and compliance officer.

Mr. Daniels will maintain his current position as Twist Bioscience's general counsel, and in his expanded role, will oversee the company's ethics and compliance programs.  He will continue to be integrally involved in providing guidance on wide-ranging aspects of the company's synthetic biology business.

"Through our expertise in DNA synthesis, Twist Bioscience continues to drive the bioeconomy, fueling far-reaching innovations that will impact health and sustainability worldwide," said Emily M. Leproust, PhD., CEO of Twist Bioscience. "Our expanding role in the bioeconomy comes with incredible responsibility to continuously evaluate the ethical impact of our business and our actions. Importantly, we view ethics and compliance as integral to our operations, with a continued focus on demonstrated leadership in biosecurity and biosafety. Ethics and Compliance will only become more important as we move forward with our pharmaceutical vertical.  With that in mind, we are formalizing the role and identified Mark as the perfect person to fill that position."

Dr. Leproust continued, "Mark's experience, including compliance work in both the pharmaceutical and semiconductor industries, will be instrumental as we scale our commercial operations to expand our game-changing technology and product offering across diverse industries.  We look forward to his continued support driving business success through an organizational culture committed to building and maintaining trust among our customers, stakeholders, regulatory agencies and the public."

Mr. Daniels joined Twist Bioscience in August 2016, bringing more than 25 years of experience as a seasoned legal officer with extensive technology and biotechnology industry expertise at Fortune 500 companies.  Prior to joining Twist Bioscience, Mark was vice president, law and deputy chief corporate compliance officer at Broadcom in Irvine, California. Before that, he spent 20 years in positions of increasing responsibility in the legal department at Amgen, where his last role was vice president and associate general counsel. Mark's law firm experience includes time at Irell & Manella in Century City, California, and Cahill Gordon & Reindel and Skadden Arps in Manhattan. Mark was a law clerk to Judge Dickran Tevrizian (ret.) on the Federal District Court in Los Angeles. He served as an adjunct professor of Law at Pepperdine University School of Law in Malibu, California where he taught Food and Drug Law.  Mark received his J.D., cum laude, from Harvard Law School, and his B.S. with honors from Cornell University. 

About Twist Bioscience

At Twist Bioscience, our expertise is accelerating science and innovation by leveraging the power of scale. We have developed a proprietary semiconductor-based synthetic DNA manufacturing process featuring a high throughput silicon platform capable of producing synthetic biology tools, including genes, oligonucleotide pools and variant libraries. By synthesizing DNA on silicon instead of on traditional 96-well plastic plates, our platform overcomes the current inefficiencies of synthetic DNA production, and enables cost-effective, rapid, high-quality and high throughput synthetic gene production, which in turn, expedites the design, build and test cycle to enable personalized medicines, pharmaceuticals, sustainable chemical production, improved agriculture production, diagnostics and biodetection. We are also developing new technologies to address large scale data storage. For more information, please visit www.twistbioscience.com. Twist Bioscience is on Twitter. Sign up to follow our Twitter feed @TwistBioscience at https://twitter.com/TwistBioscience.

SOURCE Twist Bioscience

Related Links

http://www.twistbioscience.com